NASDAQ:MNPR Monopar Therapeutics Q1 2025 Earnings Report $88.84 -0.54 (-0.60%) Closing price 04:00 PM EasternExtended Trading$88.21 -0.63 (-0.71%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Monopar Therapeutics EPS ResultsActual EPS-$0.38Consensus EPS -$0.65Beat/MissBeat by +$0.27One Year Ago EPSN/AMonopar Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMonopar Therapeutics Announcement DetailsQuarterQ1 2025Date5/13/2025TimeBefore Market OpensConference Call DateTuesday, May 13, 2025Conference Call Time4:00PM ETUpcoming EarningsMonopar Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Monopar Therapeutics Earnings HeadlinesMonopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 16, 2026 | americanbankingnews.comMonopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026August 19, 2026 | markets.businessinsider.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)Monopar Appoints Jeffrey D. Kent, M.D.August 19, 2026 | globenewswire.comMonopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'August 18, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), Achieve Life Sciences (ACHV) and OptimizeRx (OPRX)August 15, 2026 | theglobeandmail.comSee More Monopar Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Monopar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monopar Therapeutics and other key companies, straight to your email. Email Address About Monopar TherapeuticsMonopar Therapeutics (NASDAQ:MNPR) is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company’s programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity. Monopar’s lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin. Monopar is also developing MNPR-101, a urokinase plasminogen activator receptor-targeting platform intended for use in radiopharmaceutical imaging and therapy for aggressive cancers. Founded in 2014 and headquartered in Wilmette, Illinois, Monopar became a publicly traded company in 2019. Its activities have primarily centered on research, clinical development and collaborations rather than commercial product sales. The company is led by Chief Executive Officer Chandler Robinson and serves the oncology market through drug-development programs conducted primarily in the United States.View Monopar Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
